{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:56:01Z","timestamp":1788393361893,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.radonc.2025.111210","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T19:57:02Z","timestamp":1760731022000},"page":"111210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer"],"prefix":"10.1016","volume":"213","author":[{"given":"Bi-Yang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111210_b0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111210_b0010","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: Esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0015","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/cncr.24410","article-title":"Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma","volume":"115","author":"Hattangadi","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111210_b0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(21)00233-6","article-title":"Contemporary radiotherapy: present and future","volume":"398","author":"Chandra","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2025.111210_b0025","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2011.34.8904","article-title":"Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an eastern cooperative oncology group trial","volume":"29","author":"Loehrer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0030","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib the lap07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2025.111210_b0035","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0040","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0045","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2025.111210_b0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: Implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-019-1309-x","article-title":"Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results","volume":"14","author":"Reyngold","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13014-018-1158-z","article-title":"Dose escalation of radiation therapy with or without induction chemotherapy for unresectable locally advanced pancreatic cancer","volume":"13","author":"Ma","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.21873\/anticanres.13975","article-title":"Higher biologically effective dose predicts survival in sbrt of pancreatic cancer: a multicentric analysis (paula-1)","volume":"40","author":"Arcelli","year":"2020","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2025.111210_b0070","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1097\/JTO.0b013e318074de34","article-title":"Hypofractionated stereotactic radiotherapy (hypofxsrt) for stage i non-small cell lung cancer: Updated results of 257 patients in a japanese multi-institutional study","volume":"2","author":"Onishi","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0075","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0284186X.2018.1481292","article-title":"Stereotactic body radiation therapy (sbrt) improves local control and overall survival compared to conventionally fractionated radiation for stage i non-small cell lung cancer (nsclc)","volume":"57","author":"von Reibnitz","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0080","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.21037\/jgo-21-116","article-title":"Ablative radiation therapy for hepatocellular carcinoma is associated with reduced treatment- and tumor-related liver failure and improved survival","volume":"12","author":"Hilal","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0095","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1245\/s10434-014-4274-5","article-title":"The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience","volume":"22","author":"Moningi","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0105","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2025.111210_b0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0115","unstructured":"National comprehensive cancer network nccn clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 1 2015 edn (2015). In: Editor, editor^editors. Book National comprehensive cancer network nccn clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 1 2015 edn (2015)."},{"key":"10.1016\/j.radonc.2025.111210_b0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0125","unstructured":"National comprehensive cancer network (nccn) clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 2.2024. In: Editor, editor^editors. Book National comprehensive cancer network (nccn) clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 2.2024."},{"key":"10.1016\/j.radonc.2025.111210_b0130","doi-asserted-by":"crossref","first-page":"92401","DOI":"10.18632\/oncotarget.21359","article-title":"Nab-paclitaxel plus s-1 in advanced pancreatic adenocarcinoma (npspac): a single arm, single center, phase ii trial","volume":"8","author":"Shi","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2025.111210_b0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised recist guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.111210_b0140","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the radiation therapy oncology group (rtog) and the european organization for research and treatment of cancer (eortc)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.888462","article-title":"Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer","volume":"12","author":"Chuong","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0150","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online mr-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0155","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2021.02.008","article-title":"Phase i trial of stereotactic body radiation therapy dose escalation in pancreatic cancer","volume":"110","author":"Courtney","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.111210_b0160","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2004.12.022","article-title":"Phase-ii study on stereotactic radiotherapy of locally advanced pancreatic carcinoma","volume":"76","author":"Hoyer","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic mr-guided on-table adaptive radiation therapy (smart) for borderline resectable and locally advanced pancreatic cancer: a multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive mri-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - a phase ii study","volume":"197","author":"Weisz Ejlsmark","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0180","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.0460","article-title":"Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy","author":"Reyngold","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.111210_b0185","doi-asserted-by":"crossref","unstructured":"Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluoroura cil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the u.S. Intergroup\/rtog 9704 phase iii trial. Ann Surg Oncol;18: pp. 1319\u20131326.","DOI":"10.1245\/s10434-011-1630-6"},{"key":"10.1016\/j.radonc.2025.111210_b0190","doi-asserted-by":"crossref","unstructured":"Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resecti on of pancreatic cancer. New England Journal of Medicine; 350 pp. 1200\u20131210.","DOI":"10.1056\/NEJMoa032295"},{"key":"10.1016\/j.radonc.2025.111210_b0195","doi-asserted-by":"crossref","unstructured":"Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surg ery versus immediate surgery in resectable pancreatic cancer. Strahlentherapie und Onkologie;191: pp. 7\u201316.","DOI":"10.1007\/s00066-014-0737-7"},{"key":"10.1016\/j.radonc.2025.111210_b0200","doi-asserted-by":"crossref","unstructured":"Van Laethem J-L, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: A randomized eortc-400 13-22012\/ffcd-9203\/gercor phase ii study. J Clin Oncol 28:4450\u20134456.","DOI":"10.1200\/JCO.2010.30.3446"},{"key":"10.1016\/j.radonc.2025.111210_b0205","doi-asserted-by":"crossref","unstructured":"Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabi ne following pancreatic cancer resection. JAMA;304:1073.","DOI":"10.1001\/jama.2010.1275"},{"key":"10.1016\/j.radonc.2025.111210_b0210","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2147\/CMAR.S163655","article-title":"Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: a propensity score-matched analysis of a prospectively collected database","volume":"10","author":"Zhu","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.radonc.2025.111210_b0215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082213","article-title":"Survival outcomes and failure patterns in patients with inoperable non-metastatic pancreatic cancer treated with definitive radiotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Cancers (Basel)"}],"updated-by":[{"DOI":"10.1016\/j.radonc.2026.111681","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025052144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:16:12Z","timestamp":1780546572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025052144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S0167814025052144"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111210","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term outcomes of ablative stereotactic body radiation therapy for inoperable, non-metastatic pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111210","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111210"}}